<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572219</url>
  </required_header>
  <id_info>
    <org_study_id>LMB04</org_study_id>
    <nct_id>NCT02572219</nct_id>
  </id_info>
  <brief_title>Effects of a Nutraceutical Preparation on Cognitive Impairment in Hypertensive Patients</brief_title>
  <official_title>Effects of a Nutraceutical Preparation on Cognitive Impairment in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuromed IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuromed IRCCS</source>
  <brief_summary>
    <textblock>
      Aim of this randomized, double-blind clinical study is to evaluate the efficacy of a
      nutraceutical preparation on early markers of cognitive impairment, in patients affected by
      arterial hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive function assessed by neuropsychological tests</measure>
    <time_frame>6 months</time_frame>
    <description>Patients will be subjected to Montreal Cognitive Assessment (MoCA), Verbal fluency test, Word coupling test, Stroop test, and Instrumental Activities of Daily Living - IADL test. Assessments of cognitive functions will be performed by using unique score measurements defined in Units on a Scale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nutraceutical</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated with nutraceutical compound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treated with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutraceutical compound</intervention_name>
    <arm_group_label>Nutraceutical</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent;

          -  Males or females between 40 and 65 years of age;

          -  Hypertensive patients classified according to their SBP (Systolic Blood Pressure) and
             DBP (Diastolic Blood Pressure) values. Included patients will be those with stage 1
             hypertension (SBP 140-159 mmHg; DBP 90-99 mmHg) and with stage 2 hypertension (SBP
             160-179 mmHg; DBP 100-109 mmHg).

        Exclusion Criteria:

          -  Previous acute myocardial infarction (AMI);

          -  Previous stroke and/or transient ischemic attack (TIA);

          -  Diabetes mellitus;

          -  History of atrial fibrillation or other severe arrhythmias;

          -  Severe cardiovascular diseases;

          -  Renal pathologies (creatinine &gt; 1.4 mg/dL);

          -  Preexisting psychiatric pathologies;

          -  Neurodegenerative diseases, such as multiple sclerosis, lateral amyotrophic sclerosis,
             Parkinson, Alzheimer, neuromuscular pathologies, epilepsy;

          -  Diagnosis of dementia;

          -  Depression;

          -  Long-term regular use of anxiolytics drugs, antidepressant drugs, antipsychotic drugs,
             hypnoinducing drugs, cognitive stimulators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS Neuromed</name>
      <address>
        <city>Pozzilli</city>
        <state>(is)</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuromed IRCCS</investigator_affiliation>
    <investigator_full_name>Giuseppe Lembo</investigator_full_name>
    <investigator_title>prof. Giuseppe Lembo</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

